[1] Germany Boehringer Ingelheim Pharma GmbH & Co. KG. Description of afatinib dimaleate capsule[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/smshb20190415/199.pdf. [2] Jiangsu Hengrui Medicine Co., Ltd. Description of apatinib mesylate tablets[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/sms20180413/54.pdf. [3] Roche Pharma(Switzerland)Ltd. Description of bevacizumab injection [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/20180711 sms/133.pdf. [4] Roche Registration Ltd. Description of Tarceva(Erlotinib Hydrochloride Tablets) [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a230.pdf. [5] Astra Zeneca UK Limited. Description of Gefitinib Tablets[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/344.pdf. [6] Roche Pharma (Schweiz)AG. Description of rituximab injection[EB/OL].[2019-04-23]. https://db.yaozh.com/instruct/103643.html. [7] BSP Pharmaceuticals S.r.l. Description of Bortezomib for Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ypsms151012/34.pdf. [8] Roche Pharma (Schweiz) Ltd. Description of Trastuzumab Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a468.pdf. [9] Merck KGaA. Description of Cetuximab Solution for Infusion[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/2086.pdf. [10] Takeda Pharma A/S. Description of Ixazomib Citrate Capsules [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/FDA/28.pdf. [11] National Center for ADR Monitoring, State food and drug administration drug evaluation center. WHOART (WHO药品不良反应术语集)[M]. Beijing: China Medical Science and Technology Press, 2002:1-172. [12] Wang D.Active surveillance of adverse drug reaction and Its development trend[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) ,2015,12(10):600-602. [13] National Center for ADR Monitoring. The National center held a ceremony to award the national ADR monitoring outpost [EB/OL]. (2017-12-14)[2018-06-20]. http://www.cdr-adr.org.cn/xwdt/ 201712/ t20171214 19834. html. [14] Bass JM,Krens LL,Guchelaar HJ,et al.Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review[J]. Cancer Treatment Reviews,2012,38(5):505-514. [15] He H, Zhu MT.Progress of ADR monitoring in China[J]. Journal of liaoning university of chinese medicine(辽宁中医药大学学报), 2018,20(6):142-145. [16] Xiong R, Yin T, Duan CY, et al.Clinical observation of appatinib combined with systemic chemotherapy for liver metastasis of gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Pharmacy(中国药房),2019,30(6):821-824. [17] Zhang M, Shi XD, Zhao P, et al.Analysis of clinicopathologic features, diagnosis and treatment of 405 cases with gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Journal of Digestion(中华消化杂志),2016,36(12):816-821. [18] Wang FX, Shen QH, Fan GB, et al.Analysis of 190 cases of ADR reports in our hospital[J]. Chinese Pharmacy(中国药房), 2015,26(5):641-643. [19] Huang L, Ma Z.The main adverse reactions and countermeasures of molecular targeted anti-tumor drugs[J]. Journal of Hubei University of Science and Technology (Medical Edition)[湖北科技学院学报(医学版)], 2018,32(6):545-549. [20] Li D.Status quo of adverse reactions of 128 anti-tumor drugs[J]. China Medical Engineering(中国医学工程), 2019,27(3):102-104. [21] Wang NN, Bai Y, Liu H, et al.Characteristics of adverse reactions of antineoplastic drugs in 787 cases and the prognosis analysis[J]. Anti-Tumor Pharmacy(肿瘤药学), 2019,9(1):143-148. [22] Zhang Y.The manifestations and prevention and treatment of skin adverse reactions with EGFRI of targeted antitumor drugs[J]. Electronic Journal of Integrated Chinese and Western Medicine for Cardiovascular diseases(中西医结合心血管病电子杂志), 2018,6(27):198. [23] Huang CL, Guo DH, Zhu M, et al.Analysis on 9819 cases of ADR/ADE associated with quinolones in military hospitals[J]. Drug application and monitoring in China(中国药物应用与监测), 2017, 14(5):293-296. [24] Tian CH.Thinking to promote adverse drug reaction monito-ring work of medical institutions[J]. Chinese Journal of Pharma-covigilance(中国药物警戒) ,2016,13(5): 272-274. [25] Ding PN,Lord SJ,Gebski V,et al.Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, and afatinib in advanced EGFR-mutated non-small gell lung cancer[J]. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer,2017,12(4): 633-643. [26] Chen XQ, Jin YY, Tang G. Modern Pharmacology (新编药物学)[M]. Beijing: People's Medical Publishing House, 2011:17. |